Levosimendan has been treating heart failure in Europe since the early 2000s. On August 10, it failed the trial that was supposed to bring it to America.

Tenax Therapeutics reported topline results from LEVEL, a Phase 3 study of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction. The trial enrolled 241 patients across 41 sites in the United States and Canada, who were randomly assigned to the drug or placebo. Dosing was 1 mg twice daily for four weeks, then 1 mg three times daily through week 12. The main goal was improving six-minute walk distance against placebo. The trial missed it. It also missed the key secondary goal, a symptom score from the Kansas City Cardiomyopathy Questionnaire. The drug was well tolerated, with serious side effects and clinical worsening spread evenly across the two groups.

Most drugs that make a failing heart squeeze harder work by raising calcium inside the muscle cell. More calcium means a stronger squeeze, but also more oxygen burned, more irregular heartbeats, and over the long run a worse outcome. That trade-off has hung over heart failure pharmacology for decades.

Levosimendan takes a different route. It binds to troponin C, the protein that senses calcium and triggers the contraction, and makes it respond more strongly to the calcium that is already there. The cell does more with what it has, so the drug avoids the usual oxygen penalty. It is a genuinely elegant piece of pharmacology, and European clinicians have had it for twenty years.

The six-minute walk test is exactly what it sounds like. A patient walks up and down a measured hospital corridor for six minutes, and someone writes down the distance. Cardiologists and lung specialists use it because it costs nothing, needs no equipment, and measures something a patient feels in daily life, not a number on a chart.

But it is also a whole-person measurement, so it picks up everything about the person, not only the organ being treated. Knees, weight, how well someone slept, how motivated they feel, whether the corridor was busy. A drug can improve the pressures inside the pulmonary artery and push cardiac biomarkers in the right direction, both of which happened here across the full trial population, and still fail to get anyone further down the hallway.

Tenax found a substantial treatment effect in prespecified subgroups of patients with heavier disease burden, and plans to take that to the FDA in a Type C meeting, with parallel scientific advice from the EMA. This is the moment worth watching in any failed trial. A prespecified subgroup is far more defensible than one found after the fact, and a drug that moved biomarkers and blood-flow measures across the whole population clearly did something. Still, the primary endpoint is the promise a company makes before it sees the data, and this promise was missed. Everything that comes next is an argument about what the miss means, and regulators have heard that argument many times before.

Sources: Tenax Therapeutics topline results (10 August 2026, via BioSpace); Orion Corporation statement (GlobeNewswire, 10 August 2026); HCPLive; Fierce Pharma.